- 產(chǎn)品描述
TERC(3q26)基因探針
廣州健侖生物科技?有限公司
本司長(zhǎng)期供應(yīng)尼古?。商鎸帲z測(cè)試劑盒,其主要品牌包括美國(guó)NovaBios、廣州健侖、廣州創(chuàng)侖等進(jìn)口產(chǎn)品,國(guó)產(chǎn)產(chǎn)品,試劑盒的實(shí)驗(yàn)方法是膠體金方法。
我司還有很多熒光原位雜交系列檢測(cè)試劑盒以及各種FISH基因探針和染色體探針等,。
TERC(3q26)基因探針
gong頸癌是嚴(yán)重威脅婦女健康的主要惡性腫瘤,發(fā)病率居女性sheng殖系統(tǒng)惡性腫瘤的第二位。目前宮頸細(xì)胞學(xué)篩查的廣泛應(yīng)用和HPV檢測(cè)已使gong頸癌的發(fā)病率和死亡率大幅度下降,但目前的篩查程序仍存在一定的局限性。對(duì)于年輕女性來說,輕度細(xì)胞學(xué)異常很常見,且大多數(shù)會(huì)自然轉(zhuǎn)歸;HPV感染可能只是短暫的,有可能自然轉(zhuǎn)陰。更為重要的是,宮頸細(xì)胞學(xué)篩查不能很好地區(qū)分宮頸上皮內(nèi)瘤變(CIN)和預(yù)測(cè)其是否進(jìn)展。CIN發(fā)展為gong頸癌是一個(gè)長(zhǎng)期的過程,早期診斷和恰當(dāng)?shù)闹委?可能將其阻斷在CIN或早期癌階段,并*治愈。然而,并非所有的CIN病變都進(jìn)展為高度病變,而目前采用的基于形態(tài)學(xué)診斷的方法有時(shí)很難將CIN與非瘤病變、不同級(jí)別的CIN準(zhǔn)確地鑒別出來,從而導(dǎo)致過度治療或治療不足。
歡迎咨詢
歡迎咨詢
以下是我司出售的部分FISH產(chǎn)品:
3號(hào)染色體計(jì)數(shù)探針(綠色) |
7號(hào)染色體計(jì)數(shù)探針(綠色) |
17號(hào)染色體計(jì)數(shù)探針(綠色) |
10號(hào)染色體計(jì)數(shù)探針(綠色) |
X染色體檢測(cè)探針 |
Y染色體計(jì)數(shù)探針(紅色) |
13號(hào)染色體檢測(cè)探針 |
MLAA-34(13q14)基因探針 |
CCND3/IGH融合基因t (6;14)探針 |
1q21基因探針(紅色) |
15號(hào)染色體計(jì)數(shù)探針(綠色) |
2p探針(紅色) |
3p探針 |
1q探針 |
6p探針(紅色) |
8p探針 |
13q探針(紅色) |
21q探針(紅色) |
14/22號(hào)染色體探針 |
二維碼掃一掃
我司還提供:登革熱,黃熱病,基肯孔熱,西尼羅河,立次克體,無形體,蜱蟲,恙蟲,錐蟲,利什曼原蟲,RK39, 漢坦病毒,乙腦,森林腦炎,寨卡病毒 ,H7N9 ,流感,霍亂,軍團(tuán)菌,結(jié)核,諾如病毒,輪狀病毒,炭疽,O157,葡萄球菌 ,流行性出血熱,傷寒桿菌,志賀氏菌檢測(cè)試劑,!
【公司名稱】 廣州健侖生物科技有限公司
【】 楊永漢
【】
【騰訊 】
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-3室
【企業(yè)文化宣傳】
Cervical cancer is a major malignant tumor that seriously threatens the health of women. The incidence of cancer is the second most malignant tumor in female reproductive system. The wide application of cervical cytology screening and HPV detection have reduced the incidence and mortality of cervical cancer. However, there are still some limitations in the current screening program. For young women, mild cytological abnormalities are common, and most of them return naturally; HPV infection may be only transient and may naturally turn to shade. More importantly, cervical cytology screening can not be a good area for cervical intraepithelial neoplasia (CIN) and predicts its progress. The development of CIN for cervical cancer is a long-term process. Early diagnosis and proper treatment can be compley blocked at CIN or early cancer stage and compley cured. However, not all CIN lesions are progressing to high degree of disease. Currently, the morphological diagnosis method is sometimes difficult to distinguish CIN from non neoplastic lesions and CIN at different levels, which leads to over treatment or inadequate treatment.